Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ISB Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Liposomal Bupivacaine for Pain Control After Rotator Cuff Repair

NCT03692546
View directory record Official record
Conditions
Rotator Cuff Tear, Postoperative Pain
Interventions
Liposomal bupivacaine (LB)
Drug
Lead sponsor
Orthopaedic & Neurosurgery Specialists
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Greenwich, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 5, 2026, 9:04 PM EDT
Recruiting Phase 1 Interventional

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 2001
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Continuous Interscalene Block Results in Superior Recovery Throughout the First Postoperative Week

NCT01881776
View directory record Official record
Conditions
Postoperative Pain, Adverse Effects
Interventions
ISB
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine vs Dexamethasone ISB

NCT04047446
View directory record Official record
Conditions
Shoulder Pain
Interventions
Exparel 133 MG Per 10 ML Injection, Dexamethasone
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

NCT03568162
View directory record Official record
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3, Placebo - Part 1 Group 4, ISB 830 - Part 2 Group 5, Placebo - Part 2 Group 6
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
34
States / cities
Birmingham, Alabama • Clovis, California • Rolling Hills Estates, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Not applicable Interventional Results available

Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG

NCT02068820
View directory record Official record
Conditions
Endometrial Cancer
Interventions
ISB dye and standard white light imaging, ICG dye and FireFly fluorescence imaging
Device
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Phase 1 Interventional

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

NCT03309111
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 1342
Biological
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Denver, Colorado • Baltimore, Maryland • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Phase 4 Interventional

Measuring Opioid Use After Rotator Cuff Repair: Comparing the Effects of Standard vs. Extended-release Nerve Blocks

NCT05482113
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Liposomal bupivacaine, Bupivacaine Hcl 0.25% Inj
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Phase 2 Interventional Results available

Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer

NCT01771666
View directory record Official record
Conditions
Breast Cancer
Interventions
SPY Elite Imaging, Indocyanine Green, Isosulfan blue, 99technetium-sulfur colloid radiolabel
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Results available

Interscalene Block Versus Superior Trunk Block

NCT03272139
View directory record Official record
Conditions
Joint Disease, Pain, Pain, Acute, Pain, Chronic
Interventions
Bupivacaine, Ultrasound
Drug · Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 5, 2026, 9:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Postoperative Analgesia After Shoulder Replacement

NCT01003860
View directory record Official record
Conditions
Analgesia
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2009 · Synced Sep 5, 2026, 9:04 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

NCT05427812
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 5, 2026, 9:04 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

NCT03983395
View directory record Official record
Conditions
Breast Cancer
Interventions
ISB 1302 250 ng/kg, ISB 1302 325 ng/kg, ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22, ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22, ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22, ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22, ISB 1302 escalating doses,1200 ng/kg D15,22, ISB 1302 at the MTD and/or RP2D dose
Biological
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Gilbert, Arizona • Los Angeles, California • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Not applicable Interventional

Interscalene Bupivacaine With Either Liposomal Bupivacaine or Continuous Peripheral Nerve Block for Shoulder Arthroscopy

NCT03816982
View directory record Official record
Conditions
Shoulder Pain
Interventions
Single-injection bupivacaine HCl plus liposomal bupivacaine, Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Results available

Analgesia After Total Shoulder Arthroplasty

NCT01782872
View directory record Official record
Conditions
Total Shoulder Arthroplasty
Interventions
Interscalene Block (ISB) - 0.375% Ropivacaine + additives, Interscalene Block (ISB) - 0.2% Ropivacaine + additives, Interscalene Block (ISB) - 0.1% Ropivacaine + additives, Interscalene Block (ISB) - Systemic Control
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 5, 2026, 9:04 PM EDT
Recruiting Phase 4 Interventional

Buprenorphine, Clonidine, and Dexamethasone on Duration of Brachial Plexus Blocks for Upper Extremity Surgery

NCT05824832
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Interscalene block with the addition of buprenorphine, clonidine, dexamethasone, Interscalene block with buprenorphine alone
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Not applicable Interventional Results available

Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma

NCT01898403
View directory record Official record
Conditions
Recurrent Melanoma
Interventions
Indocyanine green solution, Isosulfan blue (ISB), Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)
Drug · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Sep 5, 2026, 9:04 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants

NCT03845894
View directory record Official record
Conditions
Shoulder Arthroplasty
Interventions
Liposomal bupivacaine, Bupivacaine with adjuvants
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 5, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)

NCT03913091
View directory record Official record
Conditions
Shoulder Pain
Interventions
Liposomal Bupivacaine, 0.5% Bupivacaine HCL
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 5, 2026, 9:04 PM EDT